Recently, Matwings, an AI-driven full-stack protein R&D platform, has completed over 200 million RMB in Series A+ financing. This round of financing was jointly led by CNPC Kunlun Capital, existing shareholder Yonghua Capital and Shanghai Engine Community, with follow-on investments from institutions including SDIC, XinGongXiaoJiJin, Pharmacare and Fortera Capital. Existing shareholders such as Qiming Venture Partners, GSR United Capital Runpu Medical Fund and 3E Bioventures Capital continued to increase their investments.

About Matwings                                                             

Matwings, founded in 2021 by an elite team from Shanghai Jiao Tong University, is an AI-driven full-stack protein R&D platform company. By building an unparalleled ultra-large-scale protein sequence dataset/label library, Matwings has developed a general large model for protein design on this foundation, enabling precise design of functional proteins directly tailored to industrial demands.

Centered on its self-developed large protein model as the core engine, Matwings has developed a full-stack AI protein R&D platform by integrating scientific research intelligent agents and automated laboratory equipment. The platform covers the entire workflow: market/literature/patent research, molecular design, small-scale validation, pilot-scale process optimization, and ultimately production scale-up. By fully integrating AI into industrial application scenarios, Matwings breaks through the cognitive boundaries of existing human experts, enabling faster and superior development of diverse biological products with proteins as the underlying “chips”, such as innovative drugs, healthcare products, agricultural products, functional foods, and bio-based materials.

We hope to join hands with you to create a better future.